Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine ...

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

This can primarily be attributed to: AbbVie’s revenue rose around 20% from $ ... it acquired ImmunoGen for $10.1 billion this year, giving it rights to Elahere — an ovarian cancer treatment ...

AbbVie (ABBV) reports Q3 earnings Wednesday. The acquisition of Aliada Therapeutics may boost its Alzheimer's portfolio and ...

For the quarter ended September 2024, AbbVie (ABBV) reported revenue of $14.46 billion, up 3.8% over the same period last year. EPS came in at $3.00, compared to $2.95 in the year-ago quarter.

AbbVie (ABBV) shares snapped eight consecutive sessions of losses as the stock closed up XYZ% at $XYZ. The North ...

Last year, pharmaceutical ... $1 billion less than AbbVie's acquisition of Cerevel. Still, the company survived the Rova-T ...

Revenue exposure analysis shows consistent growth trends over 10 years, indicating stability and resilience but downward over 5. Valuation metrics show AbbVie to be only slightly undervalued based ...

AbbVie stock popped Wednesday after the pharma behemoth's new king in immunology finally outpaced its grandfather drug, ...

As of Q3 2024, Humira sales were $2.2 billion globally, but AbbVie's total revenue was $14.4 billion. Its immunology portfolio (which includes all three of the medicines) grew by 3.9% year over ...